Entering text into the input field will update the search result below

agilon health: Back To Long-Term Range, Despite Underlying Market Growth

Dec. 14, 2022 7:07 PM ETagilon health, inc. (AGL)
Zach Bristow profile picture
Zach Bristow


  • agilon health, inc. is unable to return back to previous highs, losing support and buying volume.
  • This, despite a reasonably strong quarter of growth.
  • We also identify the geriatrics treatment market as a potential compounder, and thus agilon health is worth reviewing as a candidate.
  • Rate agilon health, inc. hold for now, with quantitative data supportive of the same.

Nurse checking senior woman"s vital signs in her home

MoMo Productions

Investment Summary

Here at HBI, we are mandated to provide our clients with uncorrelated equity premium for those seeking exposure to healthcare equities. We do that by searching for highly liquid diversifiers that have this tactical alpha available. That involves

This article was written by

Zach Bristow profile picture
Equity strategist, global equities, at Bernard Family Office. Analyzing market trends to tell investors what's the best investments based on macroeconomic, idiosyncratic factors.Shoot me a message to talk trade ides or portfolio construction. Disclaimer:Please remember to conduct your own due diligence.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You


Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.